Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Healthcare Fund Consonance Capital’s Top Picks For Q3 Following Monster First Half

Consonance upped its stake in Insys Therapeutics Inc (NASDAQ:INSY) by 9% as well during the second trimester, to 2.98 million shares valued at $107.19 million. Insys Therapeutics Inc (NASDAQ:INSY)’s stock has appreciated by nearly 66% on a year-to-date basis. Although some investors have become weary of the investigations into doctors’ prescribing behavior, which could have a significant impact on Insys’ Subsys, an opoid pain medication, the sales of the drug have been soaring, registering a 40% increase in the second quarter on a year-over-year basis. Moreover, promising drugs are in the pipeline, including oral dronabinol, a variation of the marijuana drug Marinol that is used to treat nausea caused by chemotherapy, and anorexia caused by HIV. The market for the drug is $150 million in annual sales. Among the funds that we track Samuel Isaly‘s Orbimed Advisors is another prominent stockholder of Insys Therapeutics Inc (NASDAQ:INSY), holding 1.24 million shares valued at $72.27 million.

After a staggering increase of 60% in its Eagle Pharmaceuticals Inc (NASDAQ:EGRX) stake, Consonance holds some 1.18 million shares valued at $95.96 million of the specialty pharmaceutical company. The holding represents 9.61% of the fund’s portfolio value and amasses about 8.4% of the company’s outstanding shares. The stock price of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has been growing faster than the universe (or thereabouts), being up by more than 370% year-to-date. The company managed to beat both the top and bottom line estimates in its recent financial results for the second quarter. Dimitry Balyasny’s Balyasny Asset Management holds about 7,055 shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) valued at $570,000 as of June 30.

Unsurprisingly, based on the staggering results of its top three picks, the returns of Consonance’s stock picks have been near the top of all the hedge funds we track at Insider Monkey. The fund’s picks in stocks with a market cap of $1 billion or greater delivered weighted average returns of 58.1% in the first half of 2015.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.